The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study

Bibliographic Details
Main Author: Jung, C
Publication Date: 2021
Other Authors: Flaatten, H, Fjolner, J, Bruno, R, Wernly, B, Artigas, A, Pinto, B, Schefold, J, Wolff, G, Kelm, M, Beil, M, Sviri, S, Heerden, P, Szczeklil, W, Czuczwar, M, Elhadi, M, Joannidis, M, Oeyen, S, Zafeiridis, T, Marsh, B, Andersen, F, Moreno, R, Cecconi, M, Leaver, S, Boumendil, A, De Lange, D, Guidet, B, COVIP Study Group
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.17/4079
Summary: Background: The COVID-19 pandemic has led highly developed healthcare systems to the brink of collapse due to the large numbers of patients being admitted into hospitals. One of the potential prognostic indicators in patients with COVID-19 is frailty. The degree of frailty could be used to assist both the triage into intensive care, and decisions regarding treatment limitations. Our study sought to determine the interaction of frailty and age in elderly COVID-19 ICU patients. Methods: A prospective multicentre study of COVID-19 patients ≥ 70 years admitted to intensive care in 138 ICUs from 28 countries was conducted. The primary endpoint was 30-day mortality. Frailty was assessed using the clinical frailty scale. Additionally, comorbidities, management strategies and treatment limitations were recorded. Results: The study included 1346 patients (28% female) with a median age of 75 years (IQR 72-78, range 70-96), 16.3% were older than 80 years, and 21% of the patients were frail. The overall survival at 30 days was 59% (95% CI 56-62), with 66% (63-69) in fit, 53% (47-61) in vulnerable and 41% (35-47) in frail patients (p < 0.001). In frail patients, there was no difference in 30-day survival between different age categories. Frailty was linked to an increased use of treatment limitations and less use of mechanical ventilation. In a model controlling for age, disease severity, sex, treatment limitations and comorbidities, frailty was independently associated with lower survival. Conclusion: Frailty provides relevant prognostic information in elderly COVID-19 patients in addition to age and comorbidities. Trial registration Clinicaltrials.gov: NCT04321265 , registered 19 March 2020.
id RCAP_735d2b068f662de34244dd25e7e40a12
oai_identifier_str oai:repositorio.chlc.pt:10400.17/4079
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP StudyHSJ UCIAgedAged, 80 and overCOVID-19 / mortality*FemaleMaleHumansCOVID-19 / therapy*Critical CareFrail Elderly / statistics & numerical data*Frailty / mortality*PrognosisProspective StudiesSurvival AnalysisBackground: The COVID-19 pandemic has led highly developed healthcare systems to the brink of collapse due to the large numbers of patients being admitted into hospitals. One of the potential prognostic indicators in patients with COVID-19 is frailty. The degree of frailty could be used to assist both the triage into intensive care, and decisions regarding treatment limitations. Our study sought to determine the interaction of frailty and age in elderly COVID-19 ICU patients. Methods: A prospective multicentre study of COVID-19 patients ≥ 70 years admitted to intensive care in 138 ICUs from 28 countries was conducted. The primary endpoint was 30-day mortality. Frailty was assessed using the clinical frailty scale. Additionally, comorbidities, management strategies and treatment limitations were recorded. Results: The study included 1346 patients (28% female) with a median age of 75 years (IQR 72-78, range 70-96), 16.3% were older than 80 years, and 21% of the patients were frail. The overall survival at 30 days was 59% (95% CI 56-62), with 66% (63-69) in fit, 53% (47-61) in vulnerable and 41% (35-47) in frail patients (p < 0.001). In frail patients, there was no difference in 30-day survival between different age categories. Frailty was linked to an increased use of treatment limitations and less use of mechanical ventilation. In a model controlling for age, disease severity, sex, treatment limitations and comorbidities, frailty was independently associated with lower survival. Conclusion: Frailty provides relevant prognostic information in elderly COVID-19 patients in addition to age and comorbidities. Trial registration Clinicaltrials.gov: NCT04321265 , registered 19 March 2020.BMCRepositório da Unidade Local de Saúde São JoséJung, CFlaatten, HFjolner, JBruno, RWernly, BArtigas, APinto, BSchefold, JWolff, GKelm, MBeil, MSviri, SHeerden, PSzczeklil, WCzuczwar, MElhadi, MJoannidis, MOeyen, SZafeiridis, TMarsh, BAndersen, FMoreno, RCecconi, MLeaver, SBoumendil, ADe Lange, DGuidet, BCOVIP Study Group2022-05-13T14:46:06Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4079eng10.1186/s13054-021-03551-3.info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-06T16:48:43Zoai:repositorio.chlc.pt:10400.17/4079Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T00:19:57.448400Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
title The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
spellingShingle The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
Jung, C
HSJ UCI
Aged
Aged, 80 and over
COVID-19 / mortality*
Female
Male
Humans
COVID-19 / therapy*
Critical Care
Frail Elderly / statistics & numerical data*
Frailty / mortality*
Prognosis
Prospective Studies
Survival Analysis
title_short The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
title_full The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
title_fullStr The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
title_full_unstemmed The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
title_sort The Impact of Frailty on Survival in Elderly Intensive Care Patients with COVID-19: the COVIP Study
author Jung, C
author_facet Jung, C
Flaatten, H
Fjolner, J
Bruno, R
Wernly, B
Artigas, A
Pinto, B
Schefold, J
Wolff, G
Kelm, M
Beil, M
Sviri, S
Heerden, P
Szczeklil, W
Czuczwar, M
Elhadi, M
Joannidis, M
Oeyen, S
Zafeiridis, T
Marsh, B
Andersen, F
Moreno, R
Cecconi, M
Leaver, S
Boumendil, A
De Lange, D
Guidet, B
COVIP Study Group
author_role author
author2 Flaatten, H
Fjolner, J
Bruno, R
Wernly, B
Artigas, A
Pinto, B
Schefold, J
Wolff, G
Kelm, M
Beil, M
Sviri, S
Heerden, P
Szczeklil, W
Czuczwar, M
Elhadi, M
Joannidis, M
Oeyen, S
Zafeiridis, T
Marsh, B
Andersen, F
Moreno, R
Cecconi, M
Leaver, S
Boumendil, A
De Lange, D
Guidet, B
COVIP Study Group
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Unidade Local de Saúde São José
dc.contributor.author.fl_str_mv Jung, C
Flaatten, H
Fjolner, J
Bruno, R
Wernly, B
Artigas, A
Pinto, B
Schefold, J
Wolff, G
Kelm, M
Beil, M
Sviri, S
Heerden, P
Szczeklil, W
Czuczwar, M
Elhadi, M
Joannidis, M
Oeyen, S
Zafeiridis, T
Marsh, B
Andersen, F
Moreno, R
Cecconi, M
Leaver, S
Boumendil, A
De Lange, D
Guidet, B
COVIP Study Group
dc.subject.por.fl_str_mv HSJ UCI
Aged
Aged, 80 and over
COVID-19 / mortality*
Female
Male
Humans
COVID-19 / therapy*
Critical Care
Frail Elderly / statistics & numerical data*
Frailty / mortality*
Prognosis
Prospective Studies
Survival Analysis
topic HSJ UCI
Aged
Aged, 80 and over
COVID-19 / mortality*
Female
Male
Humans
COVID-19 / therapy*
Critical Care
Frail Elderly / statistics & numerical data*
Frailty / mortality*
Prognosis
Prospective Studies
Survival Analysis
description Background: The COVID-19 pandemic has led highly developed healthcare systems to the brink of collapse due to the large numbers of patients being admitted into hospitals. One of the potential prognostic indicators in patients with COVID-19 is frailty. The degree of frailty could be used to assist both the triage into intensive care, and decisions regarding treatment limitations. Our study sought to determine the interaction of frailty and age in elderly COVID-19 ICU patients. Methods: A prospective multicentre study of COVID-19 patients ≥ 70 years admitted to intensive care in 138 ICUs from 28 countries was conducted. The primary endpoint was 30-day mortality. Frailty was assessed using the clinical frailty scale. Additionally, comorbidities, management strategies and treatment limitations were recorded. Results: The study included 1346 patients (28% female) with a median age of 75 years (IQR 72-78, range 70-96), 16.3% were older than 80 years, and 21% of the patients were frail. The overall survival at 30 days was 59% (95% CI 56-62), with 66% (63-69) in fit, 53% (47-61) in vulnerable and 41% (35-47) in frail patients (p < 0.001). In frail patients, there was no difference in 30-day survival between different age categories. Frailty was linked to an increased use of treatment limitations and less use of mechanical ventilation. In a model controlling for age, disease severity, sex, treatment limitations and comorbidities, frailty was independently associated with lower survival. Conclusion: Frailty provides relevant prognostic information in elderly COVID-19 patients in addition to age and comorbidities. Trial registration Clinicaltrials.gov: NCT04321265 , registered 19 March 2020.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
2022-05-13T14:46:06Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4079
url http://hdl.handle.net/10400.17/4079
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1186/s13054-021-03551-3.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833600489861677056